Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics (DE:HTD)
:HTD
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.16Last Year’s EPS
0.28Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: 2.70%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call presents a positive outlook with significant growth in revenue, hypercortisolism patient base, and promising clinical trial results. However, challenges such as net income decline, pharmacy vendor issues, and ongoing patent litigation pose risks.Company Guidance
During Corcept Therapeutics' Q1 2025 earnings call, the company reiterated its 2025 revenue guidance of $900 million to $950 million, based on a first-quarter revenue of $157.2 million, up from $146.8 million in the same period last year. Net income decreased to $20.5 million from $27.8 million in Q1 2024. They highlighted a robust growth trajectory in their hypercortisolism business, with a record rate of new prescriber base growth for five consecutive quarters. Korlym prescriptions nearly doubled compared to the previous year, despite a 13% decrease in average price per tablet due to a transition to an authorized generic. The company's cash and investments stood at $570.8 million as of March 31, 2025, and they acquired $43 million of common stock. They plan to increase their clinical specialist team to 175 by year-end to support relacorilant's launch, which is expected to generate $3 billion to $5 billion in annual revenue in the coming years.Revenue Growth
Corcept Therapeutics reported Q1 2025 revenue of $157.2 million, a 7.1% increase from $146.8 million in Q1 2024. The company reiterated its 2025 revenue guidance of $900 million to $950 million.
Hypercortisolism Screening and Growth
The company reported a rapid increase in screening for hypercortisolism, leading to a record growth in new prescribers and patients. Korlym prescriptions almost doubled compared to the same period last year.
Successful CATALYST Study
The CATALYST study showed that one in four patients with difficult-to-control diabetes have hypercortisolism, with treatment significantly improving hyperglycemia.
ROSELLA Trial Success
The ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its primary endpoint, showing a 30% reduction in risk of disease progression and improved overall survival.
Strong Financial Position
Corcept reported cash and investments of $570.8 million as of March 31, 2025.
---
DE:HTD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:HTD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | €65.18 | €62.28 | -4.45% |
Feb 26, 2025 | €60.40 | €57.42 | -4.93% |
Oct 30, 2024 | €43.98 | €37.48 | -14.78% |
Jul 29, 2024 | €33.57 | €33.33 | -0.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Corcept Therapeutics (DE:HTD) report earnings?
Corcept Therapeutics (DE:HTD) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Corcept Therapeutics (DE:HTD) earnings time?
Corcept Therapeutics (DE:HTD) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Corcept Therapeutics stock?
The P/E ratio of Corcept Therapeutics is N/A.
What is DE:HTD EPS forecast?
DE:HTD EPS forecast for the fiscal quarter 2025 (Q2) is 0.16.
---